FORM 4

obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GORDON CARL L				2. Issuer Name and Ticker or Trading Symbol Kinnate Biopharma Inc. [KNTE]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
GUKD	<u>ON CAR</u>	<u>L L</u>		-			,					X Directo	or	10% O	vner
(Last)	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/13/2022					-	Officer below)	(give title	Other (below)	specify	
103 MONTGOMERY STREET, SUITE 150															
THE PRESIDIO OF SAN FRANCISCO			<u> </u>												
(Street)				4.1	If Ame	ndment, I	Date	of Original File	ed (Month/Da	ay/Year)	Line	:)		iling (Check Ap	·
SAN FRANCI	ISCO CA	A	94129										iled by More t	than One Repo	
(City)	(S	tate)	(Zip)												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				Transactior te onth/Day/Ye	Execution Date,		Code (Instr. 5)			Beneficia	es Formally (D) (Following (I) (I	Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(111511. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rsion Date rcise (Month/Day/Year) if of titive	if any Co	, Transa Code (ransaction of ode (Instr. Derivative		Expiration Date of (Month/Day/Year) Un De		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$8.38	06/13/2022		A		20,250		(1)	06/13/2032	Common Stock	20,250	\$0.00	20,250	D ⁽²⁾	

Explanation of Responses:

- 1. 1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date.
- 2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

Remarks:

/s/ Mark A. Meltz, as attorneyin-fact

06/15/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.